Please assess the completion status of the following clinical trial:

Trial Title: VERtebral Fracture Treatment Comparisons in Osteoporotic Women

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Postmenopausal women with osteoporosis, as defined by low bone mineral density (BMD), i.e. anterior-posterior lumbar spine, total hip or femoral neck BMD ≥1.5 standard deviations below the average BMD for young, healthy, non-Hispanic, Caucasian women~* A minimum of 2 moderate or 1 severe vertebral fragility fractures (confirmed by central reader) were required~Exclusion Criteria:~* Increased risk of osteosarcoma~* History of unresolved skeletal diseases that affect bone metabolism~* History of atypical subtrochanteric or diaphyseal femoral fractures~* Abnormally high or low calcium levels~* Abnormally high parathyroid hormone (PTH) levels~* Severe vitamin D deficiency~* Abnormal thyroid function not corrected by therapy~* History of malignant neoplasms in the last 5 years~* Active liver disease, clinical jaundice~* Significant impairment of hepatic or renal function~* History of nephro- or urolithiasis~* Previous or planned kypho- or vertebroplasty~* Active or risk for osteonecrosis of the jaw~* Active or recent history of upper gastrointestinal disorders~* Unable to stand or sit in the upright position for at least 30 minutes

- Gender: FEMALE
- Minimum Age: 45 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Teriparatide (Type: EXPERIMENTAL): Teriparatide 20 microgram (µg) administered by subcutaneous (SC) injection once daily for 24 months.~Placebo given orally once weekly for 24 months.~Elemental Calcium 500 to 1000 milligram per day and Vitamin D 400 to 800 International Units per day, both administered orally once daily while receiving treatment.
- Risedronate (Type: ACTIVE_COMPARATOR): Risedronate 35 milligram (mg) administered orally once weekly for 24 months.~Placebo given by SC injection once daily for 24 months.~Elemental Calcium 500 to 1000 milligram per day and Vitamin D 400 to 800 International Units per day, both administered orally once daily while receiving treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).